A comparison of medroxyprogesterone serum concentrations by the oral or intramuscular route in patients with persistent or recurrent endometrial carcinoma

      This paper is only available as a PDF. To read, Please Download here.
      A randomized study, comparing serum medroxyprogesterone concentrations by the oral and Intramuscular routes, was performed on 22 patients with persistent or recurrent endometrial adenocarcinoma by six institutions of the Gynecologic Oncology Group. The oral group (11 patients) received cutaneous Provera (medroxyprogesterone), 50 mg three times a day, and the intramuscular group (11 patients) received 300 mg of Depo-Provera (medroxyprogesterone) weekly for at least 2 months. Serum levels were evaluated at 0, 2, 4, 6, 8, 10, and 12 hours after administration and every day for the first week and weekly thereafter for 8 weeks. The mean serum levels (nanograms per milliliter) of medroxyprogesterone in the oral group were consistently higher than the corresponding mean levels of the intramuscular group. In addition, from the first through eighth weeks, the measurements (medians) for the oral group were statistically higher than those for the intramuscular group. Although the study indicates a significant increase in serum levels achieved by the oral route, the follow-up period of patients under study is too early to evaluate its clinical effectiveness as compared to the intramuscular route.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kelly R.M.
        in: Proceedings of the Second Conference on Steroids in Cancer, Council on Pharmacy and Chemistry American Medical Association, Chicago1951: 116
        • Kistner R.W.
        Histologic effects of progestins on hyperplasia and carcinoma-in situ of the endometrium.
        Cancer. 1959; 12: 1106
        • Kelly R.M.
        • Baker W.H.
        Progestational agents in the treatment of carcinoma of the endometrium.
        N. Engl. J Med. 1961; 264: 216
        • Kistner R.W.
        • Baginsky S.
        Progestins in endometrial cancer.
        surg. forum. 1961; 12: 424
        • Varga A.
        • Henricksen E.
        Clinical and histopathological evaluation of the effect of 17-alpha-hydroxy- progesterone, 17-N-caproate on endometrial cancer.
        Obstet. Gynecol. 1961; 18: 658
        • Wentz B.W.
        Effect of progestational agents on endometrial hyperplasia and endometrial cancer.
        Obstet. Gynecol. 1964; 24: 370
        • Smith J.P.
        • Rutledge F.N.
        • Soofar S.
        Progestins in the treatment of patients with endometrial adenocarcinoma.
        Am. J. Obstet. Gynecol. 1966; 94: 977
        • Anderson D.G.
        Management of advanced endometrial adenocarcinoma with medroxyprogesterone.
        Am. J. Obstet. Gynecol. 1965; 92: 87
        • Kistner R.W.
        The Use of Progestins in Obstetrics and Gynecology. Year Book Medical Publishers, Inc, Chicago1969: 129
      1. Personal communication: The Upjohn Company, C. T. Provera Study. 1978 (SPSM Protocol No. 369, Kalamazoo, Michigan)
        • Cornette J.C.
        • Kirton K.T.
        • Duncan G.W.
        Measurement of medroxyprogesterone acetate (Provera) by radioimmunoassay.
        J Clin. Endocrinol. Metab. 1971; 31: 459